Sonoma Pharmaceuticals Inc. has released its financial results for the fiscal year ending March 31, 2025. The company reported consolidated total revenue figures, showing geographical variations. Revenues in the United States decreased by $447,000, marking a 15% decline from the previous year. In contrast, European sales saw a significant increase of $742,000, translating to a 16% rise. The growth in European revenue was attributed to a general increase in demand for Sonoma's products, particularly wound care products due to recent world events. In Asia, revenue increased by $19,000, primarily due to the timing of customer orders. Latin America showed a remarkable revenue increase of $1.236 million, driven by an upsurge in manufacturing orders. The Rest of World segment experienced a modest revenue gain of $3,000, again attributed to the timing of customer orders. No specific outlook or guidance for future financial performance was provided in the report.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.